Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3145595 | 0.98 | HDAC1 (0.75) | HDAC1HDAC6MTNR1AMTNR1BEPHX2 | |
| SCHEMBL28262492 | 0.95 | HDAC1 (0.66) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL63100 | 0.89 | HDAC1 (0.61) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL1206811 | 0.87 | HDAC1 (0.64) | HDAC1HDAC6MTNR1AMTNR1BEPHX2 | |
| SCHEMBL28188589 | 0.86 | HDAC1 (0.70) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL1206248 | 0.86 | HDAC1 (0.70) | HDAC1HDAC6MTNR1AMTNR1BCHRM2 | |
| SCHEMBL17274751 | 0.86 | HDAC1 (0.66) | HDAC1HDAC6MTNR1AMTNR1BEPHX2 | |
| SCHEMBL25035334 | 0.85 | HDAC1 (0.72) | HDAC1HDAC6MTNR1AMTNR1BEPHX2 | |
| SCHEMBL17274767 | 0.85 | HDAC1 (0.72) | HDAC1HDAC6MTNR1AMTNR1BEPHX2 | |
| SCHEMBL710937 | 0.85 | HDAC1 (0.72) | HDAC1HDAC6MTNR1AMTNR1BEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032218-A1 | HETEROCYCLIC THR-β RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREFOR | 苏州闻天医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-2621279-B1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9254292-B2 | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2012050848-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | SCHERING CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| US-7560596-B2 | Transition-metal-catalyzed carbon-nitrogen and carbon-carbon bond-forming reactions | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | HDAC1 1922/4885HDAC6 421/4885MTNR1A 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.